News >

Feasibility Results Support Launching Full Phase III PART Trial in Prostate Cancer

Ariela Katz
Published: Thursday, Jun 22, 2017

prostate cancer
Based on results of a feasibility study, researchers in the United Kingdom have decided to move forward with a full randomized controlled trial comparing partial prostate ablation (PA) with radical prostatectomy (RP) in patients with intermediate-risk prostate cancer, according to a presentation at the 2017 American Urological Association Annual Meeting.

In terms of QoL data, initial responses suggested that there are some potential health gains for patients who received PA compared with RP. However, in terms of essential function and QoL as time went on, there was no significant difference in patient perception.
Leslie T, Davies L, Elliott D, et al. The PART trial—a phase III study comparing Partial prostate Ablation versus Radical prosTatectomy (PART) in intermediate risk prostate cancer—early data from the feasibility study. Presented at: 2017 American Urological Association Annual Meeting; May 12-16, 2017; Boston, MA. Abstract PD56-08.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication